STAAR Surgical Company (STAA) has a MoatMap StockRank of 64/100 based on Quality (53/100), Value (23/100), and Momentum (72/100) factor scores. The current signal is HOLD. STAAR Surgical has a strong product in implantable Collamer lenses, but it lacks direct alignment with our 18-month macro themes and is currently facing growth normalization in key markets like China.
STAAR Surgical Company designs, develops, manufactures, and markets implantable lenses for the eye, primarily its proprietary EVO Visian Implantable Collamer Lens (ICL) for vision correction. The company holds a leadership position in the premium refractive vision correction market due to its unique, patented ICL technology offering superior visual outcomes for suitable patients. It benefits from high barriers to entry in ophthalmology and growing market acceptance of its advanced lens solutions.
| Price | $29.87 |
| Market Cap | $1.4B |
| P/E (Forward) | 30.24 |
| Price/Book | 4.29 |
| Return on Equity | -6.0% |
| Return on Invested Capital | -12.0% |
| Debt/Equity | 10.58 |
| Gross Margin | 76.9% |
| Operating Margin | 18.7% |
| Revenue Growth | 119.6% |
| Free Cash Flow | $-18M |
STAAR Surgical Company operates in the Medical Instruments & Supplies industry, part of the Healthcare sector (United States).